Compare Stocks: HALO, RVMD, ALNY, and BIIB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$249.59 +1.2%	$245.17	$197.81 ▼ $495.55	$33.40B	0.31	1.46 million shs	933,260 shs
BIIB Biogen	$226.36 -0.5%	$212.48	$135.39 ▼ $229.19	$33.44B	0.17	1.20 million shs	1.03 million shs
HALO Halozyme Therapeutics	$115.22 +2.5%	$98.92	$61.22 ▼ $116.85	$13.08B	0.88	1.91 million shs	3.16 million shs
RVMD Revolution Medicines	$199.86 +4.8%	$200.03	$42.18 ▼ $224.31	$42.84B	1.4	2.92 million shs	4.06 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-2.04%	+2.99%	+4.45%	-15.92%	-45.75%
BIIB Biogen	+0.96%	+5.33%	+4.31%	+12.66%	+63.33%
HALO Halozyme Therapeutics	-2.34%	+3.69%	+3.50%	+54.79%	+44.95%
RVMD Revolution Medicines	-1.10%	-2.64%	-9.85%	+7.06%	+331.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$249.59 +1.2%	$245.17	$197.81 ▼ $495.55	$33.40B	0.31	1.46 million shs	933,260 shs
BIIB Biogen	$226.36 -0.5%	$212.48	$135.39 ▼ $229.19	$33.44B	0.17	1.20 million shs	1.03 million shs
HALO Halozyme Therapeutics	$115.22 +2.5%	$98.92	$61.22 ▼ $116.85	$13.08B	0.88	1.91 million shs	3.16 million shs
RVMD Revolution Medicines	$199.86 +4.8%	$200.03	$42.18 ▼ $224.31	$42.84B	1.4	2.92 million shs	4.06 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-2.04%	+2.99%	+4.45%	-15.92%	-45.75%
BIIB Biogen	+0.96%	+5.33%	+4.31%	+12.66%	+63.33%
HALO Halozyme Therapeutics	-2.34%	+3.69%	+3.50%	+54.79%	+44.95%
RVMD Revolution Medicines	-1.10%	-2.64%	-9.85%	+7.06%	+331.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.87	Moderate Buy	$367.20	47.28% Upside
BIIB Biogen	2.56	Moderate Buy	$230.14	1.07% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-21.02% Downside
RVMD Revolution Medicines	2.96	Moderate Buy	$230.15	15.48% Upside

Current Analyst Ratings Breakdown

Latest HALO, RVMD, ALNY, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	RVMD Revolution Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$267.00
9/21/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/21/2026	RVMD Revolution Medicines	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$225.00 ➝ $265.00
9/10/2026	BIIB Biogen	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$242.00
9/10/2026	BIIB Biogen	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Reduce	$165.00 ➝ $175.00
9/10/2026	RVMD Revolution Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Overweight	$255.00
9/9/2026	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$215.00 ➝ $230.00
9/8/2026	ALNY Alnylam Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$230.00 ➝ $260.00
9/3/2026	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$225.00 ➝ $245.00
9/2/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.98	$2.77 per share	90.00	$5.97 per share	41.76
BIIB Biogen	$9.89B	3.40	$22.86 per share	9.96	$124.45 per share	1.83
HALO Halozyme Therapeutics	$1.40B	9.38	$4.79 per share	24.13	$0.42 per share	274.93
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	$8.44 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	46.33	25.70	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	40.29	14.13	2.49	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	34.50	12.38	0.44	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest HALO, RVMD, ALNY, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
HALO Halozyme Therapeutics	13.50	2.71	2.31
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
HALO Halozyme Therapeutics	97.79%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
HALO Halozyme Therapeutics	2.50%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
RVMD Revolution Medicines	883	214.34 million	198.05 million	Optionable

HALO, RVMD, ALNY, and BIIB Headlines

Recent News About These Companies

Andra AP fonden Has $5.28 Million Stock Holdings in Revolution Medicines, Inc. $RVMD

September 24 at 3:05 AM | marketbeat.com

Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?

September 23 at 3:24 AM | finance.yahoo.com

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Bank of America Analyst Says

September 23 at 1:30 AM | americanbankingnews.com

Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE

September 22 at 10:24 PM | finance.yahoo.com

Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?

September 22 at 10:24 PM | finance.yahoo.com

44,928 Shares in Revolution Medicines, Inc. $RVMD Acquired by Nykredit A S

September 22 at 3:19 AM | marketbeat.com

Bank of America Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

September 21 at 1:53 PM | marketbeat.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $67,940.84 in Stock

September 21 at 5:10 AM | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Insider Sells $2,786,969.12 in Stock

September 21 at 4:09 AM | americanbankingnews.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $1,109,567.56 in Stock

September 21 at 4:09 AM | americanbankingnews.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) COO Sells $989,625.08 in Stock

September 21 at 4:09 AM | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) CFO Sells $807,519.72 in Stock

September 21 at 4:09 AM | americanbankingnews.com

Revolution Medicines, Inc.(NasdaqGS:RVMD) added to FTSE All-World Index

September 21 at 2:34 AM | marketscreener.comM

Revolution Medicines, Inc.(NasdaqGS:RVMD) added to FTSE All-World Index

September 21 at 2:34 AM | marketscreener.comM

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells 341 Shares of Stock

September 19, 2026 | insidertrades.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Moderate Buy" from Analysts

September 19, 2026 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Moderate Buy" from Analysts

September 19, 2026 | marketbeat.com

Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

September 18, 2026 | marketbeat.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 4,053 Shares

September 18, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) COO Sells 4,967 Shares of Stock

September 18, 2026 | marketbeat.com

Stephen Michael Kelsey Sells 5,569 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

September 18, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HALO, RVMD, ALNY, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$249.59 +3.08 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$245.50 -4.09 (-1.64%)

As of 05:37 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$226.36 -1.17 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$227.78 +1.42 (+0.63%)

As of 05:38 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics NASDAQ:HALO

$115.22 +2.78 (+2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$115.32 +0.11 (+0.09%)

As of 05:32 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Revolution Medicines NASDAQ:RVMD

$199.86 +9.12 (+4.78%)

Closing price 04:00 PM Eastern

Extended Trading

$199.45 -0.41 (-0.21%)

As of 05:17 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, RVMD, ALNY, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, RVMD, ALNY, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, RVMD, ALNY, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, RVMD, ALNY, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HALO, RVMD, ALNY, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HALO, RVMD, ALNY, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HALO, RVMD, ALNY, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HALO, RVMD, ALNY, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Halozyme Therapeutics NASDAQ:HALO

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools